Litcius/Paper detail

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, Stéphane de Botton, Maria R. Baer, Gary J. Schiller, Roland B. Walter, Marina Kremyanskaya, Kristen Pettit, Stephen A. Strickland, Blake Tomkinson, Marilyn Tabachri, Mollie Leoni, Stephen Dale, Eunice S. Wang

2022Blood71 citationsDOI

Topics & Concepts

Refractory (planetary science)Myeloid leukemiaMedicinePhases of clinical researchLeukemiaCancer researchInternal medicineOncologyChemotherapyBiologyAstrobiologyAcute Myeloid Leukemia ResearchChronic Myeloid Leukemia TreatmentsLung Cancer Treatments and Mutations
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia | Litcius